131 related articles for article (PubMed ID: 17627380)
21. Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing--Atlanta, Denver, Raleigh-Durham, and Seattle, 2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2004 Jul; 53(27):603-6. PubMed ID: 15254451
[TBL] [Abstract][Full Text] [Related]
22. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
[TBL] [Abstract][Full Text] [Related]
23. Management of women at high risk of hereditary breast cancer in the Veneto Regional Program for Prevention.
Del Sole A; Cinquetti S; Fedato C; Montagna M; Russo F; Sbrogiò LG; Zorzi M
Epidemiol Prev; 2015; 39(4 Suppl 1):99-101. PubMed ID: 26499424
[TBL] [Abstract][Full Text] [Related]
24. Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer.
Robson ME
Cancer Control; 2002; 9(6):457-65. PubMed ID: 12514563
[TBL] [Abstract][Full Text] [Related]
25. ["Screening" in special situations. Assessing predictive genetic screening for hereditary breast and colorectal cancer].
Jonas S; Wild C; Schamberger C
Z Arztl Fortbild Qualitatssich; 2003 Feb; 97(1):67-71. PubMed ID: 12669692
[TBL] [Abstract][Full Text] [Related]
26. Development of genetic testing for breast, ovarian and colorectal cancer predisposition: a step closer to targeted cancer prevention.
Eccles DM
Curr Drug Targets; 2011 Dec; 12(13):1974-82. PubMed ID: 21158705
[TBL] [Abstract][Full Text] [Related]
27. Living with genetic test results for hereditary breast and ovarian cancer.
Hamilton R; Williams JK; Skirton H; Bowers BJ
J Nurs Scholarsh; 2009; 41(3):276-83. PubMed ID: 19723276
[TBL] [Abstract][Full Text] [Related]
28. Genetic testing and the family.
Van Riper M
J Midwifery Womens Health; 2005; 50(3):227-33. PubMed ID: 15895001
[TBL] [Abstract][Full Text] [Related]
29. Maximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2.
Jeffers L; Morrison PJ; McCaughan E; Fitzsimons D
Eur J Oncol Nurs; 2014 Aug; 18(4):411-8. PubMed ID: 24731853
[TBL] [Abstract][Full Text] [Related]
30. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
31. Women's decisions regarding management of breast cancer risk.
MacDonald DJ
Medsurg Nurs; 2002 Aug; 11(4):183-6. PubMed ID: 12219430
[TBL] [Abstract][Full Text] [Related]
32. Hereditary breast and ovarian cancer: research on how women respond to genetic testing.
Bingham R
Nurs Womens Health; 2012; 16(4):319-24. PubMed ID: 22900808
[TBL] [Abstract][Full Text] [Related]
33. 'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.
Werner-Lin A; Hoskins LM; Doyle MH; Greene MH
Health (London); 2012 Nov; 16(6):636-54. PubMed ID: 22547552
[TBL] [Abstract][Full Text] [Related]
34. Pharmacoprevention for hereditary breast and ovarian cancer.
Cazzaniga M; Bonanni B
Minerva Ginecol; 2016 Oct; 68(5):517-35. PubMed ID: 26928419
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT
Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846
[TBL] [Abstract][Full Text] [Related]
36. Attitudes toward genetic testing for cancer risk after genetic counseling and decision support: a qualitative comparison between hereditary cancer types.
Wakefield CE; Kasparian NA; Meiser B; Homewood J; Kirk J; Tucker K
Genet Test; 2007; 11(4):401-11. PubMed ID: 18294057
[TBL] [Abstract][Full Text] [Related]
37. Psychological opportunities and hazards in predictive genetic testing for cancer risk.
Codori AM
Gastroenterol Clin North Am; 1997 Mar; 26(1):19-39. PubMed ID: 9119438
[TBL] [Abstract][Full Text] [Related]
38. Risk of breast and ovarian cancer in women with strong family histories.
Srivastava A; McKinnon W; Wood ME
Oncology (Williston Park); 2001 Jul; 15(7):889-902; discussion 902, 905-7, 911-13. PubMed ID: 11499690
[TBL] [Abstract][Full Text] [Related]
39. Issues in the genetic assessment of predispositions for familial breast and ovarian cancer.
Mark HF; McGowan KD
Cytobios; 1996; 87(351):229-35. PubMed ID: 9214724
[TBL] [Abstract][Full Text] [Related]
40. Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result.
Bonadona V; Saltel P; Desseigne F; Mignotte H; Saurin JC; Wang Q; Sinilnikova O; Giraud S; Freyer G; Plauchu H; Puisieux A; Lasset C
Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):97-104. PubMed ID: 11815406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
